Chronic News and Research

RSS

Innovative treatments for bowel dysfunction

Twenty percent of all Albertans are plagued by symptoms of diarrhea, constipation, abdominal pain, bloating, and gas. More than an inconvenience for many, these problems are rarely discussed in public, leaving sufferers feeling isolated. Yet bowel symptoms can be disabling, greatly impairing quality of life.

15 Sep 2009

IBC offers coverage for H1N1 and seasonal flu vaccines

In an effort to help keep members healthy and flu-free this year, Independence Blue Cross (IBC) will offer coverage for the administration costs of the H1N1 (swine flu) vaccine when it becomes available. In addition, IBC will continue to cover seasonal flu vaccine.

15 Sep 2009

NORD urges members of Congress to pass comprehensive health reform legislation

On behalf of the 30 million Americans who are affected by one of the nearly 7,000 rare disorders, the National Organization for Rare Disorders (NORD) urges you to pass comprehensive health reform legislation to assure that every American has access to affordable, meaningful health insurance coverage. Failure to pass such long-overdue legislation this year would be devastating for people with rare diseases, and for millions of others burdened by chronic illness.

15 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.

14 Sep 2009

B. Braun Medical to showcase its Prontosan Wound Irrigation Solution at the SAWC Fall Event

B. Braun Medical Inc. (B. Braun) said today healthcare professionals can now place orders for Prontosan(R) Wound Irrigation Solution and Gel with PHMB (Polyhexanide), a solution used for cleaning wounds as well as moistening and lubricating absorbent wound dressings.

From B. Braun Melsungen AG 14 Sep 2009

New data confirm link between Epstein-Barr virus and multiple sclerosis

Over the last 40 years, Epstein-Barr virus (EBV) has been repeatedly associated with multiple sclerosis and other autoimmune diseases. During the 2nd European Congress of Immunology ECI 2009 held in Berlin, Francesca Aloisi, Istituto Superiore di Sanità, Rome, will present new data that further support the link. In the brain lesions of patients with multiple sclerosis her team found abnormal accumulation of EBV infected B lymphocytes.

14 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

Altair announces positive Phase I results for AIR645 in treating asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.

14 Sep 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

ALR Technologies receives patent application approval for its Health-E-Connect communications system

ALR Technologies (OTCBB: ALRT) announces that it has received notice from the US Patent and Trademark Office that ALRT has been granted approval of its patent application regarding patient compliance and remote monitoring of patient's use of nebulizer compressors.

14 Sep 2009

Concept of wellness can yield greater savings

According to a new survey released today, 90 percent of plan sponsors believe that minimal attention to personal health and increased incidence of chronic illness such as diabetes and heart disease are at the root of rising health care costs.

14 Sep 2009

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 and Phase 2a studies at the ERS Annual Congress in Vienna, Austria, September 12-16, 2009.

14 Sep 2009

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

WillWalk to raise funds for human stem cell trials for people with SCI

WillWalk, an Austin based non-profit organization has committed itself to be at the forefront of ending Paralysis. WillWalk will raise $3 million to help fund the first non-controversial human stem cell trials for people with Spinal Cord Injury (SCI).

14 Sep 2009

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

14 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

Extremity Trauma Clinical Research Consortium for treating major limb injuries

The Johns Hopkins Bloomberg School of Public Health has been awarded $18.4 million by the Orthopaedic Extremity Trauma Research Program (OETRP) of the U.S. Department of Defense to establish an Extremity Trauma Clinical Research Consortium.

14 Sep 2009

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Teva Pharmaceutical Industries Ltd. and Active Biotech today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.

14 Sep 2009

Chronic News and Research

Innovative treatments for bowel dysfunction

IBC offers coverage for H1N1 and seasonal flu vaccines

NORD urges members of Congress to pass comprehensive health reform legislation

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

B. Braun Medical to showcase its Prontosan Wound Irrigation Solution at the SAWC Fall Event

New data confirm link between Epstein-Barr virus and multiple sclerosis

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

Altair announces positive Phase I results for AIR645 in treating asthma

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

ALR Technologies receives patent application approval for its Health-E-Connect communications system

Concept of wellness can yield greater savings

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

WillWalk to raise funds for human stem cell trials for people with SCI

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Phase III clinical trial results of DAR-31 published

Influenza patients treated with Tamiflu has higher survival rates

Extremity Trauma Clinical Research Consortium for treating major limb injuries

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News